Clinical

Dr Arrowsmith discusses the role immune checkpoint inhibitors play in NSCLC therapy, both as monotherapy and in combination therapy.

The FDA Wednesday approved betibeglogene autotemcel (Zynteglo), the first cell-based gene therapy for the treatment of adult and pediatric patients with beta-thalassemia who require regular red blood cell transfusions.

Dr Feldman describes the populations that are most at risk of developing CKD.

Jeffrey Feldman, MD, and Rajiv Agarwal, MD, MS, provide an overview of chronic kidney disease (CKD) and its prevalence.

Treatment with anti-interleukin (IL)-17A inhibitors for psoriasis consistently improved outcomes across primary and secondary endpoints compared with all other approved biologics, and researchers also found differences between anti-IL-17A inhibitors.

While noting that providers and their patients should be aware of the potential risk, the researchers underscored that the risk of new-onset psoriasis due to tumor necrosis factor-α inhibitor (TNFi) treatment appears to be rare and that strategies do not need to change for patients with immune-mediated inflammatory diseases such as inflammatory bowel disease (IBD) and/or rheumatoid arthritis (RA).

The case describes hemophagocytic lymphohistiocytosis (HLH), which occurred in a young boy in Italy with spinal muscular atrophy, who was treated with onasemnogene abeparvovec.

Dr Palella Jr highlights how clinicians support patient access to PrEP and what his experiences have shown him about patient adherence with the available oral therapies.

Carl Schmid, an HIV/PrEP advocate, provides an overview of PrEP therapy; Frank J. Palella Jr, MD, a clinician focused on HIV and infectious disease, delves into the diagnostic process.

Symptoms associated with cold agglutinin disease fluctuated throughout the course of the disease, and many patients were not satisfied with management measures.

Kanwal Raghav, MD, MBBS, provides his closing insights, with a focus on HER2-targeted therapy uptake in metastatic colorectal cancer.

HER2+ targeted therapy outcomes are evaluated, particularly when combined with prior or subsequent chemotherapy.

Patients with symptoms of asthma, regardless of physiological confirmation, experienced worse vascular outcomes and greater cardiovascular risk, which may be due to short-acting beta agonist (SABA) use, according to the results of a recent study.

Despite advances made against the disease, researchers note that breast cancer still remains a top cause of cancer-related mortality in women around the world.

Patrick Burnett, MD, PhD, FAAD, chief medical officer of Arcutis Biotherapeutics, discusses the need for increased research and awareness on intertriginous disease in psoriasis.

Three approaches—prophylactic immunoglobin, antibiotics, and vaccinations—were investigated for their effectiveness at infection prevention in 3 hematological malignancies.

Dr Haumschild leads an overview of updates to ACC guidelines directing treatment of patients with heart failure.

Drs Uppal and Januzzi explore benefits of population health programs for treating chronic conditions associated with heart failure.

Drs Oskouei and Alboustani discuss implications of multiple biosimilars for adalimumab and how indications are extrapolated for a biosimilar.

Drs Atheer Kaddis and Mariam Alboustani delve into biosimilar conversion programs, including switching policies for interchangeability.

The therapy for intrahepatic cholangiocarcinoma (ICC) led to responses in about a quarter of patients and disease control in 85%.

The case of warm autoimmune hemolytic anemia (AIHA) highlights the potential for life-threatening acute hemolysis if patients do not receive timely treatment.

Policy observers and industry stakeholders debate the possible spillover effects of Medicare drug pricing reform in the employer-based insurance market; a California federal judge rules Walgreens could be held liable for not investigating suspicious orders of opioids in San Francisco; a blood test performed the day of a traumatic brain injury (TBI) can predict which patients may die and who may survive with a disability.